Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness

Clinical Pharmacology: Advances and Applications

Volumn 7, Issue , 2015, Pages 97-102

  Kiuchi, Shunsuke ^a   Hisatake, Shinji ^a   Kawasaki, Muneyasu ^b   Hirashima, Osamu ^b   Kabuki, Takayuki ^a   Yamazaki, Junichi ^a   Ikeda, Takanori ^a  

^a Department of Cardiovascular Medicine ^*  (Japan)

^b Misato Central General Hospital   (Japan)

Author keywords

Calcium channel blocker; Cardio ankle vascular index; Renin angiotensin aldosterone system inhibitor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ARTICLE; BLOOD PRESSURE; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE;

EID: 84944206751     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S81880     Document Type: Article

References (21)

1. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101–107.
2. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25: 932–943.
3. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J. 2008;72:598–604.
4. Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb. 2007;14:278–286.
5. Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on cardio-ankle vascular index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb. 2009;16:621–626.
6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
7. Ogihara T, Kikuchi K, Matsuoka H, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3–107.
8. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases; J Atheroscler Thromb. 2014; 21(4):296–298. 2012.
9. Seino Y, Nanjo K, Tajima N et al: Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–228.
10. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620–625.
11. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349:594–598.
12. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–1331.
13. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32:2499–2506.
14. Narumi H, Takano H, Shindo S, et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res. 2011;34:62–69.
15. Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res. 2009;32:575–580.
16. Ogihara T, Matsuzaki M, Umemoto S, et al; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res. 2012;35:441–448.
17. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.
18. Suzuki K, Ishizuka N, Miyashita H, Shirai K. For standardization of the cardio-ankle vascular index (CAVI) as a noninvasive, blood pressure-independent test of atherosclerosis epidemiological study on reference values and their validity. Niigata J Med Technol. 2008;48:2–9. Japanese.
19. Takano Y, Ueyama T, Ishikura F. Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α ⋅ β blocker. J Cardiol. 2012;60:18–22.
20. Kishi T, Hirooka Y, Konno S, Sunagawa K. Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension. Clin Exp Hypertens. 2009;31:241–249.
21. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26:201–208.